<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS109159</article-id>
<article-id pub-id-type="doi">10.1101/2020.12.23.424149</article-id>
<article-id pub-id-type="archive">PPR257813</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Noske</surname>
<given-names>G. D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Nakamura</surname>
<given-names>A. M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gawriljuk</surname>
<given-names>V. O.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fernandes</surname>
<given-names>R. S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lima</surname>
<given-names>G. M. A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="fn" rid="FN1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rosa</surname>
<given-names>H. V. D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pereira</surname>
<given-names>H. D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zeri</surname>
<given-names>A. C. M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nascimento</surname>
<given-names>A. A. F. Z.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Freire</surname>
<given-names>M. C. L. C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oliva</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Godoy</surname>
<given-names>A. S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Institute of Physics of Sao Carlos, University of Sao Paulo, Av. Joao Dagnone, 1100 - Jardim Santa Angelina, Sao Carlos, 13563-120, Brazil</aff>
<aff id="A2">
<label>2</label>BioMAX, MAX IV Laboratory, Fotongatan 2, Lund, 224 84, Sweden</aff>
<aff id="A3">
<label>3</label>Brazilian Synchrotron Light Laboratory (LNLS), Brazilian Center for Research in Energy and Materials (CNPEM), Zip Code 13083-970, Campinas, Sao Paulo, Brazil</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence to: <email>andregodoy@ifsc.usp.br</email>; <email>oliva@ifsc.usp.br</email>
</corresp>
<fn id="FN1" fn-type="present-address">
<label>†</label>
<p id="P1">
<italic>current address:</italic> Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>25</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>23</day>
<month>12</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P2">SARS-CoV-2 is the causative agent of COVID-19. The dimeric form of the viral main protease is responsible for the cleavage of the viral polyprotein in 11 sites, including its own N and C-terminus. Although several mechanisms of self-cleavage had been proposed for SARS-CoV, the lack of structural information for each step is a setback to the understanding of this process. Herein, we used X-ray crystallography to characterize an immature form of the main protease, which revealed major conformational changes in the positioning of domain-three over the active site, hampering the dimerization and diminishing its activity. We propose that this form preludes the cis-cleavage of N-terminal residues within the dimer, leading to the mature active site. Using fragment screening, we probe new cavities in this form which can be used to guide therapeutic development. Furthermore, we characterized a serine site-directed mutant of the main protease bound to its endogenous N and C-terminal residues during the formation of the tetramer. This quaternary form is also present in solution, suggesting a transitional state during the C-terminal trans-cleavage. This data sheds light in the structural modifications of the SARS-CoV-2 main protease during maturation, which can guide the development of new inhibitors targeting its intermediary states.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P3">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of COVID-19, a highly infectious disease that rapidly spread causing a global pandemic. SARS-CoV-2 is an enveloped RNA virus belonging to the β-lineage of coronaviruses, which includes SARS-CoV and Middle East (MERS-CoV) respiratory viruses <sup>
<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R3">3</xref>
</sup>. The viral genome is a single-stranded positive RNA comprising about 30,000 nucleotides, that shares 82% sequence similarity with SARS-CoV <sup>
<xref ref-type="bibr" rid="R4">4</xref>
</sup>. The replicase gene (ORF1ab) encodes two overlapping polyproteins (pp1a and pp1ab) that are required for viral replication and transcription <sup>
<xref ref-type="bibr" rid="R5">5</xref>
</sup>.</p>
<p id="P4">The main protease (M<sup>pro</sup>), also known as 3C-like protease (3CL<sup>pro</sup>) is a viral cysteine protease specific for glutamine at the S1 subsite, showing variable recognition preferences at S2 (Leu/Phe/Met/Val) and S2’ subsites (Ser/Ala/Gly/Asn) <sup>
<xref ref-type="bibr" rid="R6">6</xref>
</sup>. M<sup>pro</sup> is responsible for the maturation of pp1a and pp1ab in at least 11 characterized sites, including its auto-processing at the N and C terminus, which is essential for its activity and dimerization <sup>
<xref ref-type="bibr" rid="R7">7</xref>–<xref ref-type="bibr" rid="R9">9</xref>
</sup>. Due to its essential role in viral replication, M<sup>pro</sup> is one of the most well characterized non-structural proteins of SARS-CoV-2. In addition, its unique features of cleavage site recognition and the absence of closely related homologues in humans, identify M<sup>pro</sup> as a major target for antiviral drug development <sup>
<xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R11">11</xref>
</sup>.</p>
<p id="P5">Although M<sup>pro</sup> activity is crucial to viral biology, its self-maturation process is still poorly understood. Several biochemical and crystallographic studies on native and mutated forms of SARS-CoV M<sup>pro</sup> tried to elucidate its maturation mechanism (reviewed in <sup>
<xref ref-type="bibr" rid="R12">12</xref>
</sup>), by evaluating if the N and C-terminus processing occurs within a dimer (<italic>cis</italic>-cleavage) or between two distinct dimers (<italic>trans</italic>-cleavage). The first 2005 model suggested that M<sup>pro</sup> probably forms a small amount of active dimer after autocleavage that immediately enables the catalytic site to act on other cleavage sites in the polyprotein <sup>
<xref ref-type="bibr" rid="R13">13</xref>
</sup>. In 2010, based on the observation that dimerization of mature M<sup>pro</sup> is enhanced by the presence of substrates, Li and colleagues proposed that after the translation, two M<sup>pro</sup> protomers form a transient dimer which is stabilized by binding the N-terminal site of its substrate (another M<sup>pro</sup> in polyprotein) and further cleave to free its N-terminus <sup>
<xref ref-type="bibr" rid="R14">14</xref>
</sup>. In addition, Chen et al. (2010) suggested that the N-terminal autocleavage might only need two immature forms of M<sup>pro</sup> in monomeric polyproteins to form an intermediate dimer that is not related to the active dimer of the mature enzyme <sup>
<xref ref-type="bibr" rid="R15">15</xref>
</sup>.</p>
<p id="P6">Herein, we used X-ray crystallography integrated with biochemical techniques to investigate the self-maturation process of SARS-CoV-2 <italic>M</italic>
<sup>pro</sup>. The construct of M<sup>pro</sup> containing N-terminal insertions produced an immature form of the enzyme (IMT M<sup>pro</sup>), unable to form a dimer, that showed a reduced enzymatic activity. We used fragment screening to probe new cavities for drug development in this construct. The inactive mutant C145S with inserted native N-terminal residues (C145S M<sup>pro</sup>) produced a form of the protein that behaves as monomers, dimers, trimers and tetramers in solution. Crystals of the tetrameric form revealed details of how M<sup>pro</sup> self-processes its N and C-terminal residues. All forms of the enzyme revealed important conformation changes that can guide direct-acting drug development.</p>
</sec>
<sec id="S2">
<title>Activity and biochemical characterization</title>
<p id="P7">A general strategy to produce SARS-CoV-2 M<sup>pro</sup> is to maintain its self-cleavage N-terminal portion and add the HRV-3C cleavage site with a histidine-tag at the C-terminal portion. We successfully used ammonium sulfate precipitation followed by ion exchange chromatography to obtain pure M<sup>pro</sup>, simplifying the protocol to one that takes less than 8 h and with a final yield of ~2.5 mg/L of culture. The SARS-CoV-2 IMT M<sup>pro</sup> was obtained by adding a non-cleavable sequence (Gly-Ala-Met) at the N-terminal Ser1 of M<sup>pro</sup>, and purified by a similar protocol. The SARS-CoV-2 IMT M<sup>pro</sup> was produced as a soluble protein, yielding ~80 mg/L of culture. To further investigate the role of N-terminal residues in the maturation of M<sup>pro</sup>, we designed a construct containing the mutated C145S residue with its native cleavage peptide of M<sup>pro</sup> (Ser-4,Ala-3,Val-2,Leu-1,Gln0↓) at the N-terminal of Ser1 (<xref ref-type="supplementary-material" rid="SD1">Fig. S1</xref>). During gel filtration, two M<sup>pro</sup> peaks were identified with mass consistent with a monomer and a tetramer (<xref ref-type="supplementary-material" rid="SD1">Fig. S1</xref>).</p>
<p id="P8">M<sup>pro</sup> and IMT M<sup>pro</sup> demonstrate to be active and able to recognize and cleave the fluorogenic substrate (<xref ref-type="fig" rid="F1">Fig. 1</xref>), with <italic>Km</italic> values of 16.4 ± 2.3 μM and 34.3 ± 2.2 μM, respectively. IMT M<sup>pro</sup> exhibited only 6% of the catalytic efficiency compared with mature M<sup>pro</sup>. As previously reported, the M<sup>pro</sup> N-terminal is fundamental for dimerization and any additional residues would reduce or even abolish its activity <sup>
<xref ref-type="bibr" rid="R9">9</xref>,<xref ref-type="bibr" rid="R16">16</xref>–<xref ref-type="bibr" rid="R18">18</xref>
</sup>. As expected, C145S M<sup>pro</sup> has only shown residual activity (<xref ref-type="fig" rid="F1">Fig. 1</xref>). All three M<sup>pro</sup> constructs exhibited similar thermal-stability profiles, indicating similar folding (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
<p id="P9">Analysis in solution using SEC-MALS suggests that M<sup>pro</sup> behaves as a dimer in the tested conditions, as expected <sup>
<xref ref-type="bibr" rid="R11">11</xref>
</sup>. For IMT M<sup>pro</sup>, the additional residues at N-terminal seem to prevent dimerization completely. For C145S M<sup>pro</sup>, however, the additional residues allow the protein to adopt multiple conformational states ranging from monomers to tetramers (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
<p id="P10">Despite the site-direct mutagenesis of the C145S M<sup>pro</sup>, the enzyme exhibited residual proteolytic activity which allowed us to observe self-processing by SDS-PAGE in the course of two days. Despite the efficiency of M<sup>pro</sup>, its addition to the reaction does not seem to enhance significantly the rate of self-cleavage, suggesting cis-cleavage as main mechanism of N-terminal cleavage (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
</sec>
<sec id="S3">
<title>Crystal structure of M<sup>pro</sup>
</title>
<p id="P11">M<sup>pro</sup> was crystallized in several conditions and its X-ray structure was determined at 1.46 Å in <italic>C</italic>21 space group. All 306 residues were refined at the electron density to a final <italic>R</italic>work/<italic>R</italic>free of 0.16/0.18, with 99% of Ramachandran in favored positions (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). The crystal asymmetric unit contains one monomer which could be symmetry expanded to the biological dimer, following the same pattern of the majority of known structures deposited in PDB (r.m.s.d of 0.2 Å vs PDB 5RGG, for all Cα 306). The M<sup>pro</sup> protomers are formed by three domains (DI, DII and DIII), with its catalytic region located at the double-barreled DII <sup>
<xref ref-type="bibr" rid="R9">9</xref>
</sup> (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>).</p>
</sec>
<sec id="S4">
<title>Crystal structure of IMT M<sup>pro</sup>
</title>
<p id="P12">The crystal structure of IMT M<sup>pro</sup> at 1.6 Å was determined using 3 merged datasets (<xref ref-type="supplementary-material" rid="SD1">Fig S3</xref>, <xref ref-type="supplementary-material" rid="SD1">S4</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>) in <italic>P</italic>212121 space group, with two molecules in the asymmetric unit, packed in similar shape to the known biological unit of M<sup>pro</sup>. The structure was refined to a final <italic>R</italic>work/<italic>R</italic>free of 0.20/0.22, with 97% of Ramachandran in favored positions (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). In the recent published structures of GM-M<sup>pro</sup>, both apo and ligand-complexes exhibited minor differences with the mature form <sup>
<xref ref-type="bibr" rid="R16">16</xref>
</sup>. However, in our structure there are distinguishable differences in the overall structure, especially in the position of DIII helices (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Although IMT M<sup>pro</sup> asymmetric unit resembles the biological dimer form of native protein, PISA<sup>
<xref ref-type="bibr" rid="R19">19</xref>
</sup> analysis indicate that the dimer packing is unstable in solution, with an interface area of 1,256 Å<sup>
<xref ref-type="bibr" rid="R2">2</xref>
</sup> (vs 1,557 Å of M<sup>pro</sup>), calculated free energy ΔG of -13.4 kcal/mol (vs -14.9 kcal/mol of M<sup>pro</sup>) for 26 potential hydrogen bonds (vs 49 of M<sup>pro</sup>) and 5 potential salt bridges (vs 10 of M<sup>pro</sup>).</p>
<p id="P13">While IMT M<sup>pro</sup> DI and DII are less affected by the N-terminal insertion (r.m.s.d of 0.34 Å vs Mpro<sup>mat</sup> for Cα of 1-184), DIII appears to adopt a more open conformation relative to M<sup>pro</sup> (r.m.s.d of 1.33 Å for Cα of 201-301) (<xref ref-type="fig" rid="F2">Fig. 2</xref>), with the interfacing residues Ala285 at a distance of 10 Å in the IMT M<sup>pro</sup> (vs 5.2 Å in M<sup>pro</sup>) (<xref ref-type="supplementary-material" rid="SD1">Fig. S5</xref>). This conformation is more accentuated at chain A where the electron density of the N-terminal insertion is clearly visible in the model. For this chain, the N-terminal insertion pushes chain A helices αF and αH further of chain B active site, opening a cleft for Phe140 rises to the surface of the molecule, leading to major conformation alterations of the chain B active site souring residues, such as Glu166, Pro168 and Gln189 (<xref ref-type="fig" rid="F2">Fig. 2</xref> and <xref ref-type="supplementary-material" rid="SD1">S6</xref>). The plasticity of SARS-CoV-2 M<sup>pro</sup> active site was already reported when apo X-ray structures collected at cryo and room temperatures were compared <sup>
<xref ref-type="bibr" rid="R20">20</xref>
</sup>, and its expected given the broad spectrum of endogenous substrates that M<sup>pro</sup> is expected to process. However, the IMT M<sup>pro</sup> revealed major structural alterations in the oxyanion hole, likely affecting enzyme processing. Despite the significant changes of the active site, relative position of the catalytic dyad Cys145-His41 remains unchanged in this form (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p>
</sec>
<sec id="S5">
<title>Fragment Screening of M<sup>pro</sup> immature</title>
<p id="P14">Recently, a small-fragment library of more than 1,250 unique fragments were screened against SARS-CoV-2 M<sup>pro</sup>, identifying 74 high-value fragment hits, including 23 non-covalent and 48 covalent hits in the active site, and 3 hits close to the dimerization interface <sup>
<xref ref-type="bibr" rid="R21">21</xref>
</sup>. In here, we applied the same technique to probe new druggable cavities in IMT M<sup>pro</sup>. Although the difference in scale of our experiment, we were able to identify five distinguishable sites in this form of the protein (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Site #1 is the active site of chain A, in which fragment f2xe03 was identified interacting with Glu166 N and Cys145 S. Interesting, a unique cavity marked as Site #3 was identified in our experiments, bound to fragment f2xg02 by Arg4 main chain O. That cavity lies between the interface of chains A and B, and is not present in M<sup>pro</sup> which adopt a more closed conformation. This new site and fragment could serve as an anchor for development of new inhibitors targeting M<sup>pro</sup> dimerization process, a mode of action that was too date only theorized <sup>
<xref ref-type="bibr" rid="R22">22</xref>
</sup>. Details about data processing and statistics are given in <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>.</p>
</sec>
<sec id="S6">
<title>Crystal structure of C145S M<sup>pro</sup> in complex with N and C-terminal residues</title>
<p id="P15">The tetramer peaks were crystallized and X-ray structure determined at 2.8 Å and <italic>R</italic>work/<italic>R</italic>free of 0.20/0.24 (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>), revealing a new crystal form in which N-terminal chain B residues are trimmed in the active site of chain A, occupying subsites S1-S5 (<xref ref-type="fig" rid="F4">Fig. 4</xref>). Despite the site directed mutagenesis of the catalytic cysteine to serine, electron density shows that Gln0 and Ser1 are non-covalently bound in the amino region, clearly indicating that the N-terminal cis-cleavage was completed. At the S1 subsite, Gln0 NE2 interacts with Glu166 OE1 by a hydrogen bound (2.7 Å), while Gln0 form interacts with Ser145 in the position of the native oxyanion hole (<xref ref-type="fig" rid="F4">Fig. 4</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S8</xref>-<xref ref-type="supplementary-material" rid="SD1">S9</xref>). To accommodate the hydrophobic sidechain of Leu-1 at P2, Met49 and Met165 are pushed further of each other (<xref ref-type="supplementary-material" rid="SD1">Fig. S10</xref>), leading to a more opened groove of this subsite relatively to the apo-state, explaining the ability of this subsite to accommodate a variety of hydrophobic side chain residues, such as Leu, Met, Ile, Val and Phe <sup>
<xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R23">23</xref>
</sup>. Yet, from the eleven endogenous recognition sites of coronaviruses, S2 Leu carrying sequences are the ones in which M<sup>pro</sup> display higher catalytic efficiency, highlighting the importance of this conformation for drug design. At subsites S3-S5, the interactions of Val-2, Ala-3 and Ser-4 are mainly maintained by hydrogen bounds between the polar residues of protein and peptide side chains (<xref ref-type="fig" rid="F4">Fig. 4</xref>), which explains the ability of M<sup>pro</sup> to recognize a large variety of chain sequences at those positions.</p>
<p id="P16">The crystal structure of C145S M<sup>pro</sup> revealed another important step in the maturation process of M<sup>pro</sup>. At the same time that chain B N-terminal additional residues are processed by chain A, its C-terminal residues (301-306) are almost 180° twisted from its original position (<xref ref-type="supplementary-material" rid="SD1">Fig. S11</xref>) and trimmed in the active site of a symmetric related chain B (<xref ref-type="fig" rid="F4">Fig. 4</xref>) a phenomenon that was also recently described by another group in both native and in a C145A M<sup>pro</sup> mutant <sup>
<xref ref-type="bibr" rid="R24">24</xref>
</sup>. During this event, two C145A M<sup>pro</sup> dimers appear to be linked by the interaction of the C-terminal and a respective active site, assuming a tetrameric conformation (<xref ref-type="fig" rid="F5">Fig. 5</xref>). Within the active site, Gln306 occupies the respective position of Gln0 at S1, while S2 is occupied by Phe305, increasing the distance between Met49 and Met165 relatively to chain A bound to N-terminal (<xref ref-type="supplementary-material" rid="SD1">Fig. S10</xref>). As the N-terminal residues, subsites S3-S5 interactions with C-terminal are mainly maintained by hydrogen bounds between main chains (<xref ref-type="fig" rid="F4">Fig 4</xref>).</p>
</sec>
<sec id="S7">
<title>The maturation process of M<sup>pro</sup> and its impact on Drug discovery</title>
<p id="P17">M<sup>pro</sup> is firstly produced as the Nsp5 domain of the viral polyproteins before they are proteolytically processed into 15 or 16 non-structural proteins <sup>
<xref ref-type="bibr" rid="R12">12</xref>
</sup>. Immediately after translation, the immature form of M<sup>pro</sup> would contain both N and C-terminal insertions that need self-processing to generate the mature form of the enzyme <sup>
<xref ref-type="bibr" rid="R13">13</xref>
</sup>.</p>
<p id="P18">The biochemical assays of IMT M<sup>pro</sup> revealed that a minor insertion at the N-terminal produces a protein form that behaves as a monomer in solution and its almost depleted of enzymatic activity, even though the general folding remains similar to the full mature form. The same process occurs to C145S M<sup>pro</sup> with native N-terminal inserted residues, although, in this case, a slow cleavage of the N-terminus results in the formation of dimers overtime (<xref ref-type="fig" rid="F1">Fig. 1</xref>). It is important to highlight that when M<sup>pro</sup> is added to C145S M<sup>pro</sup>, the N-terminal cleavage and dimer formation does not seem to be enhanced, strongly suggesting that this initial maturation step is a <italic>cis</italic>-cleavage event. This is in agreement with the model proposed by Li and colleagues (2010) in which two M<sup>pro</sup> form a transient dimer that is stabilized by the binding the N-terminal site of its substrate (another M<sup>pro</sup> in polyprotein) and further cleave to free its N terminus <sup>
<xref ref-type="bibr" rid="R14">14</xref>
</sup>.</p>
<p id="P19">After the active site region is matured (or even concomitantly), dimeric M<sup>pro</sup>, C-terminal seem to assume an unusual twisted position (<xref ref-type="supplementary-material" rid="SD1">Fig. S11</xref>), allowing it to be docked into the active site of another mature or half-mature M<sup>pro</sup> dimer (<xref ref-type="fig" rid="F4">Fig. 4</xref>). In this step, the trans-cleavage processing of the C-terminal residues would serve as an anchor for a transitory tetrameric state of the protein, herein captured with the construct of the mutant C145S M<sup>pro</sup> with the processing of the N-terminal residues (<xref ref-type="fig" rid="F5">Fig. 5</xref>). As a result, full mature M<sup>pro</sup> is produced and its ready to process other parts of the viral polyprotein. During all those maturation processes, both M<sup>pro</sup> active site and surface undergo significant conformational changes, which could guide targeted drug development (<xref ref-type="fig" rid="F6">Fig. 6</xref> and <xref ref-type="supplementary-material" rid="SD1">Scheme S1</xref>). Our results not only shed light in the self-maturation process of SARS-CoV-2 M<sup>pro</sup>, but also bring the perspective of developing drugs targeting intermediate states of this enzyme.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS109159-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66542" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S8">
<title>Acknowledgements</title>
<p>Authors acknowledge SIRUS (Campinas, Brazil) proposal 20200014. F2X Entry was obtained with resources from Federal Ministry of Education and Research (BMBF), while FragMAXlib with resources from Swedish Research Council (VR).</p>
<sec id="S9">
<title>Funding</title>
<p>This project was funded by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES – project 88887.516153/2020-00) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP projects 2013/07600-3, 2015/16811-3 and 2016/19712-9).</p>
</sec>
</ack>
<sec id="S10" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P20">Structure factors and atomic coordinates have been deposited with the protein data bank with accession codes PDB ID 7KFI, 7KPH, 7KVG, 7LFE, 7LDX, 7LFP, 7KVL and 7KVR. Other data are available from the corresponding author upon reasonable request.</p>
</sec>
<fn-group>
<fn fn-type="con" id="FN2">
<p id="P21">
<bold>Author contributions:</bold>
</p>
<p id="P22">ASG conceived this project. GDN performed biochemical and biophysical experiments. GDN, ASG, AMN, VOG and GMAL performed crystallographic experiments and analysis. ASG, GDN, AMN, VOG, GO and RSF wrote this manuscript. HVDR performed SEC-MALS experiments. Other authors supported experiments and data analysis.</p>
</fn>
<fn id="FN3" fn-type="conflict">
<p id="P23">
<bold>Competing interests:</bold>
</p>
<p id="P24">The authors declare no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>727</fpage>
<lpage>733</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lou Yang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>XG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HD</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>ZW</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>A new coronavirus associated with human respiratory disease in China</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>265</fpage>
<lpage>269</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorbalenya</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Baric</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>de Groot</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gulyaeva</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Haagmans</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Lauber</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Leontovich</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Neuman</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Penzar</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2</article-title>
<source>Nat Microbiol</source>
<year>2020</year>
<volume>5</volume>
<fpage>536</fpage>
<lpage>544</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nyodu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Maurya</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Saxena</surname>
<given-names>SK</given-names>
</name>
</person-group>
<source>Coronavirus Disease 2019 (COVID-19)</source>
<year>2020</year>
<fpage>23</fpage>
<lpage>31</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase</article-title>
<source>J Biol Chem</source>
<year>2004</year>
<volume>279</volume>
<fpage>1637</fpage>
<lpage>1642</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshino</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Yasuo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Sekijima</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Identification of key interactions between SARS-CoV-2 main protease and inhibitor drug candidates</article-title>
<source>Sci Rep</source>
<year>2020</year>
<volume>10</volume>
<fpage>12493</fpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Ziebuhr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wadhwani</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mesters</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs</article-title>
<source>Science</source>
<year>2003</year>
<volume>300</volume>
<fpage>1763</fpage>
<lpage>1767</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Curth</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Drosten</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sauerhering</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rox</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors</article-title>
<source>Science</source>
<year>2020</year>
<volume>368</volume>
<fpage>409</fpage>
<lpage>412</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur</article-title>
<source>Nat Struct Mol Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>529</fpage>
<lpage>532</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sacco</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Hurst</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Townsend</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Szeto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tarbet</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Marty</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</article-title>
<source>Cell Res</source>
<year>2020</year>
<volume>30</volume>
<fpage>678</fpage>
<lpage>692</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Activation and maturation of SARS-CoV main protease</article-title>
<source>Protein Cell</source>
<year>2011</year>
<volume>2</volume>
<fpage>282</fpage>
<lpage>290</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hsu</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Shr</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>AHJ</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>PH</given-names>
</name>
</person-group>
<article-title>Mechanism of the maturation process of SARS-CoV 3CL protease</article-title>
<source>J Biol Chem</source>
<year>2005</year>
<volume>280</volume>
<fpage>31257</fpage>
<lpage>31266</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Maturation mechanism of severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase</article-title>
<source>J Biol Chem</source>
<year>2010</year>
<volume>285</volume>
<fpage>28134</fpage>
<lpage>28140</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jonas</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Higenfeld</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode</article-title>
<source>Protein Cell</source>
<year>2010</year>
<volume>1</volume>
<fpage>59</fpage>
<lpage>74</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anand</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palm</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Mesters</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Siddell</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Ziebuhr</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra α-helical domain</article-title>
<source>EMBO J</source>
<year>2002</year>
<volume>21</volume>
<fpage>3213</fpage>
<lpage>3224</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Bartlam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Production of Authentic SARS-CoV Mpro with Enhanced Activity: Application as a Novel Tag-cleavage Endopeptidase for Protein Overproduction</article-title>
<source>J Mol Biol</source>
<year>2007</year>
<volume>366</volume>
<fpage>965</fpage>
<lpage>975</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krissinel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Henrick</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Inference of macromolecular assemblies from crystalline state</article-title>
<source>J Mol Biol</source>
<year>2007</year>
<volume>372</volume>
<fpage>774</fpage>
<lpage>797</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kneller</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>G</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Jedrzejczak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stols</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Langan</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Joachimiak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Coates</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kovalevsky</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>7</fpage>
<lpage>12</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douangamath</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fearon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Gehrtz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Krojer</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lukacik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Owen</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Strain-Damerell</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Aimon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ábrányi-Balogh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Brandão-Neto</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease</article-title>
<source>Nat Commun</source>
<year>2020</year>
<volume>11</volume>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Goyal</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy</article-title>
<source>ACS Comb Sci</source>
<year>2020</year>
<volume>22</volume>
<fpage>297</fpage>
<lpage>305</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rut</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Groborz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Zmudzinski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pawlik</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jochmans</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Neyts</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Młynarski</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hilgenfeld</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging</article-title>
<source>Nat Chem Biol</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Worrall</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Vuckovic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosell</surname>
<given-names>FI</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Caveney</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Ban</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cherkasov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Paetzel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Strynadka</surname>
<given-names>NCJ</given-names>
</name>
</person-group>
<article-title>Crystallographic structure of wild-type SARS-CoV- 2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site</article-title>
<source>Nat Commun</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1038/s41467-020-19662-4</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig 1</label>
<caption>
<p>(a) Time-course reactions of M<sup>pro</sup> constructs against fluorogenic peptide substrate. (b) Differential scanning fluorimetry of M<sup>pro</sup> constructs. M<sup>pro</sup> is shown as blue squares, IMT M<sup>pro</sup> is shown as red spheres and C145S M<sup>pro</sup> is shown as black triangles (c) Size exclusion chromatography elution profiles with overlaid calculated molar mass from elution peaks. M<sup>pro</sup> (blue) elutes as a single peak with a calculated molecular mass consistent with a dimer. IMT M<sup>pro</sup> (red) exhibits a single peak with a mass compatible with a monomer in solution. The monomeric SEC peak of C145S M<sup>pro</sup> (grey) elutes as an equilibrium between dimers and monomers in solution. The tetrameric SEC peak of C145S M<sup>pro</sup> (black) contains peaks of monomers, dimer, trimers and tetramers. (d) SDS-PAGE of N-terminal cleavage over time from C145S M<sup>pro</sup>. At top, reaction containing 10 µM C145S M<sup>pro</sup>, and at the bottom the same reaction supplemented with 5 nM M<sup>pro</sup>.</p>
</caption>
<graphic xlink:href="EMS109159-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig 2</label>
<caption>
<p>(a) Overview of DIII region from IMT M<sup>pro</sup> (chain A yellow and B cyan) superposed with M<sup>pro</sup> (grey ghost). N-terminal residues are depicted as spheres. (b) Rotated view showing IMT M<sup>pro</sup> DIII from a distinct angle. (c) Active site residues of IMT M<sup>pro</sup> chain B (cyan cartoon) superposed with M<sup>pro</sup>. Catalytic residues are depicted as yellow sticks. N-terminal chain A residues are depicted as spheres. M<sup>pro</sup> structure and residues are shown as a grey ghost.</p>
</caption>
<graphic xlink:href="EMS109159-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig 3</label>
<caption>
<p>(a) Location of IMT M<sup>pro</sup> probing fragments identified during screening. Chain A is colored as yellow surface, chain B as cyan surface. Fragments are depicted as red spheres. (b) Contact details of identified fragments. Chain A is colored as yellow cartoon and chain B as cyan cartoon. Fragments are depicted as yellow sticks. Residues forming polar contacts are depicted as green lines. Contacts are depicted as black dashes.</p>
</caption>
<graphic xlink:href="EMS109159-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig 4</label>
<caption>
<p>(a) C145S M<sup>pro</sup> chain A active site (cyan surface) in complex with processed N-terminal residues (yellow sticks). Main interacting residues are depicted as blue lines. (b) C-terminal peptide (yellow) main interactions with C145S M<sup>pro</sup> chain A active site residues (blue). (c) C145S M<sup>pro</sup> chain B active site (blue surface) in complex with processed C-terminal residues (yellow sticks). Main interacting residues are depicted as blue lines. (d) C-terminal peptide (yellow) main interactions with C145S M<sup>pro</sup> chain B active site residues (blue). For (b) and (d), the 2mFo-DFc electron density contoured at 0.8σ. Ser1 from respective dimerization partners are depicted with green letters. *Ser145 is the site-direct mutant of Cys145. Simulated annealing omit map is available in <xref ref-type="supplementary-material" rid="SD1">Fig S7</xref>.</p>
</caption>
<graphic xlink:href="EMS109159-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig 5</label>
<caption>
<p>Overview of the tetrameric intermediary formed by C145S M<sup>pro</sup> during self-processing. Chain A is colored as yellow surface, chain B as cyan surface. <italic>Trans</italic>-cleavage M<sup>pro</sup> partner is show as green cartoon. N-terminal residues are depicted as blue spheres, and C-terminal residues are depicted as red spheres.</p>
</caption>
<graphic xlink:href="EMS109159-f005"/>
</fig>
<fig id="F6" position="float">
<label>Fig 6</label>
<caption>
<p>(a) Scheme containing steps of SARS-CoV-2 M<sup>pro</sup> self-maturation process. At first, two protomers assembly as an immature dimer during N-terminal cis-cleavage. After processing, M<sup>pro</sup> has a mature active site, which allows the stabilization of the dimeric form. The dimer C-terminal is them trans-cleaved by another full or half mature dimer, producing the full mature form of M<sup>pro</sup>. (b) Surface view of chain B active site from immature form. (c) Surface view of chain A active site during N-terminal residues recognition. (d) Surface view of chain B active site during C-terminal residues recognition. (e) Surface view of full mature M<sup>pro</sup> active site.</p>
</caption>
<graphic xlink:href="EMS109159-f006"/>
</fig>
</floats-group>
</article>
